Sakurai Masatoshi, Watanuki Shintaro, Kato Jun, Hashida Risa, Yamane Yusuke, Karigane Daiki, Mitsuhashi Takayuki, Murata Mitsuru, Ueno Hironori, Nakazato Tomonori, Okamoto Shinichiro, Mori Takehiko
Division of Hematology, Department of Medicine, Keio University School of Medicine, Japan.
Laboratory Medicine, Keio University School of Medicine, Japan.
Intern Med. 2018 Nov 15;57(22):3299-3302. doi: 10.2169/internalmedicine.0807-18. Epub 2018 Jul 6.
The prognosis of acute promyelocytic leukemia (APL) has been improved by the combination of all-trans retinoic acid (ATRA) with chemotherapy. Nonetheless, relapse occurs in a certain proportion of patients, mostly within three to four years after treatment. We herein report a patient treated with ATRA and chemotherapy achieving remission who relapsed approximately 17 years after the treatment. A literature review identified 5 additional reported cases of APL relapse after more than 10 years. None of them presented with generally established risk factors for relapse, such as a high leukocyte count. The potential for late relapse of APL occurring more than 10 years after treatment should be recognized.
全反式维甲酸(ATRA)与化疗联合应用改善了急性早幼粒细胞白血病(APL)的预后。尽管如此,仍有一定比例的患者会复发,大多在治疗后三到四年内。我们在此报告一例接受ATRA和化疗后达到缓解的患者,其在治疗后约17年复发。文献回顾发现另外5例报告的APL在10年以上复发的病例。这些病例均未出现公认的复发危险因素,如白细胞计数高。应认识到APL在治疗10年以上后出现晚期复发的可能性。